Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK Study of Stapokibart (CM310) in Healthy Subjects
NCT06171048Phase 1Not yet recruiting
- Sponsor
- Keymed Biosciences
- Start
- Apr 2024
- Primary completion
- Apr 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of stapokibart in atopic dermatitis (AD) (2 arms), sponsored by Keymed Biosciences. Primary endpoint: Maximum Concentration at 6 weeks. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
stapokibart
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT06171048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06171048.